Annual report pursuant to Section 13 and 15(d)

Segment Reporting - Net Revenue and Operating Profit of Each Segment (Detail)

v3.3.1.900
Segment Reporting - Net Revenue and Operating Profit of Each Segment (Detail) - USD ($)
 12 Months Ended
Nov. 30, 2015
Nov. 30, 2014
Segment Reporting Information [Line Items]    
Total net revenue $ 21,091,431 $ 20,126,546
Total cost of sales 5,630,865 5,632,041
Total operating profit 2,933,224 1,981,234
Total depreciation and amortization 92,110 171,334
Total depreciation and amortization 241,208 377,008
Total interest expense 1,303,872 1,151,459
Total income tax benefit (expense) (7,156,822) 123,526
Total other comprehensive income 169,932 0
Total assets 19,497,946 10,209,586
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member]    
Segment Reporting Information [Line Items]    
Total net revenue 20,620,138 20,126,546
Total cost of sales 5,276,125 5,632,041
Total operating profit 2,842,957 1,981,234
Total depreciation and amortization 218,568 377,008
Total interest expense 1,277,815 1,151,459
Total income tax benefit (expense) 7,166,789 (123,526)
Total other comprehensive income 169,932  
Total assets 16,697,621 $ 10,209,586
Prepacyte CB [Member]    
Segment Reporting Information [Line Items]    
Total net revenue 471,293  
Total cost of sales 354,740  
Total operating profit 90,267  
Total depreciation and amortization 22,640  
Total interest expense 26,057  
Total income tax benefit (expense) (9,967)  
Total assets $ 2,800,325